- Home
- ELAB vs QLGN Comparison
ELAB vs QLGN Comparison
Compare ELAB & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELAB
- QLGN
- Stock Information
- Founded
- ELAB 2020
- QLGN 1996
- Country
- ELAB United States
- QLGN United States
- Employees
- ELAB N/A
- QLGN N/A
- Industry
- ELAB
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- ELAB
- QLGN Health Care
- Exchange
- ELAB Nasdaq
- QLGN Nasdaq
- Market Cap
- ELAB 3.2M
- QLGN 3.1M
- IPO Year
- ELAB 2023
- QLGN N/A
- Fundamental
- Price
- ELAB $4.41
- QLGN $1.76
- Analyst Decision
- ELAB
- QLGN
- Analyst Count
- ELAB 0
- QLGN 0
- Target Price
- ELAB N/A
- QLGN N/A
- AVG Volume (30 Days)
- ELAB 2.3M
- QLGN 43.3K
- Earning Date
- ELAB 08-13-2025
- QLGN 08-14-2025
- Dividend Yield
- ELAB N/A
- QLGN N/A
- EPS Growth
- ELAB N/A
- QLGN N/A
- EPS
- ELAB N/A
- QLGN N/A
- Revenue
- ELAB N/A
- QLGN N/A
- Revenue This Year
- ELAB N/A
- QLGN N/A
- Revenue Next Year
- ELAB N/A
- QLGN N/A
- P/E Ratio
- ELAB N/A
- QLGN N/A
- Revenue Growth
- ELAB N/A
- QLGN N/A
- 52 Week Low
- ELAB $4.31
- QLGN $1.61
- 52 Week High
- ELAB $1,842.11
- QLGN $10.45
- Technical
- Relative Strength Index (RSI)
- ELAB 30.58
- QLGN 35.42
- Support Level
- ELAB $4.31
- QLGN $1.66
- Resistance Level
- ELAB $5.42
- QLGN $1.77
- Average True Range (ATR)
- ELAB 0.97
- QLGN 0.08
- MACD
- ELAB -0.25
- QLGN 0.04
- Stochastic Oscillator
- ELAB 1.16
- QLGN 28.57
About ELAB Elevai Labs Inc.
PMGC Holdings Inc advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's program, QN-302, is an investigational small-molecule G-quadruplexes (G4)-selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells.